Archives
-
Carbenoxolone Disodium: Product Overview
2026-10-06
Carbenoxolone disodium (SKU A8389) is described by APExBIO as an 11β-hydroxysteroid dehydrogenase inhibitor and research compound related to glucocorticoid access, gap junction communication, and Cx43 signaling. No matched paper evidence was provided, so performance, selectivity, and biological applicability remain unestablished.
-
Carbenoxolone Disodium: Product Overview
2026-10-06
Carbenoxolone disodium (SKU A8389) is an APExBIO-listed research compound described as an 11β-hydroxysteroid dehydrogenase inhibitor. The supplied information supports product identity and conceptual scope, but no matched paper evidence is available to verify biological performance, selectivity, or disease-model relevance.
-
PFKM and Mitochondrial Remodeling in Osteogenesis
2026-10-05
A source-grounded overview of a 2026 study linking PFKM suppression with mitochondrial remodeling, calcium signaling, mitochondrial quality control, and bone formation. The discussion compares the study’s mechanistic and in vivo evidence while defining the limits of translating these findings to human therapy or fluorescent reporter applications.
-
Risedronate Sodium in Bone and Lung Research
2026-10-05
Risedronate Sodium is an established nitrogen-containing bisphosphonate and FPP synthase inhibitor in bone metabolism research. A 2021 rat study explored a nebulized microsphere formulation for emphysema, reporting reduced macrophage-associated pathology, but the evidence remains preclinical and does not establish human efficacy or safety.
-
Dutasteride: Dual 5α-Reductase Inhibitor
2026-10-04
Dutasteride is a dual 5-alpha-reductase inhibitor that reduces formation of dihydrotestosterone from testosterone. Its strongest evidence supports androgen-pathway studies and benign prostatic hyperplasia research, while cell and animal findings require cautious interpretation before translation to prostate cancer research.
-
CNQX: AMPA/Kainate Signaling Workflows
2026-10-01
CNQX enables selective interruption of AMPA- and kainate-receptor signaling without making NMDA receptors the primary pharmacological target. This guide translates that selectivity into practical electrophysiology, circuit-mapping, and neurocardiovascular workflows, with concentration planning and troubleshooting guidance.
-
Gap19 Workflow for Cx43 Hemichannel Studies
2026-10-01
Gap19 is a selective connexin 43 hemichannel blocker for separating Cx43 hemichannel signaling from gap-junction communication. This practical workflow connects astrocyte ATP-release assays, macrophage inflammation studies, and cerebral ischemia models with controls that improve mechanistic confidence.
-
Risedronate Sodium: Applied Research Workflows
2026-10-01
Risedronate Sodium supports reproducible bone-resorption studies and a translational inhalation workflow for emphysema research. This guide connects FPPS inhibition with practical formulation, cell-based, aerosol, and animal-model decisions while highlighting controls and troubleshooting steps.
-
Gap19: Selective Connexin 43 Hemichannel Blocker
2026-09-30
Gap19 enables targeted interrogation of Cx43 hemichannel signaling while preserving gap junction communication, making it useful for astrocyte ATP-release assays, neuroprotection in cerebral ischemia, and inflammation studies. This guide translates reference findings into practical workflows, controls, and troubleshooting strategies for reproducible experiments.
-
Cy3 TSA Fluorescence System Kit for HCC Biology
2026-09-29
The Cy3 TSA Fluorescence System Kit enables sensitive spatial analysis of miR-3180, SCD1, and CD36 in hepatocellular carcinoma models. This article translates lipid-metabolism findings into a rigorous fluorescence workflow while distinguishing signal amplification from biological causation.
-
Sodium Orthovanadate for Phosphorylation Assays
2026-09-29
Sodium Orthovanadate (Na3VO4) helps preserve labile tyrosine phosphorylation during lysis, immunoblotting, and kinase experiments. Its reversible inhibition and water-based formulation also support EDTA rescue controls that distinguish phosphorylation loss from true biological differences.
-
Cx43/NF-κB Signaling in AngII-Driven Macrophage Polarization
2026-09-28
The reference study identifies connexin 43 (Cx43) and NF-κB p65 as a linked signaling axis through which angiotensin II drives RAW264.7 macrophages toward a pro-inflammatory M1 phenotype. By combining phenotypic assays with pharmacological inhibition using BAY117082, Gap26, and Gap19, the work provides a mechanistic framework for studying Cx43-dependent inflammatory signaling while also highlighting the need to distinguish hemichannel effects from broader Cx43 channel functions.
-
HIV-1 Protease Autoprocessing in Drug Discovery
2026-09-28
Huang and colleagues developed a cell-based AlphaLISA assay to screen for inhibitors of HIV-1 protease autoprocessing, a precursor-processing step distinct from inhibition of mature protease. The assay met a high-throughput screening quality benchmark, identified known HIV protease inhibitors, and reproduced resistance patterns in mutant precursors, providing a tool for investigating antiviral drug discovery and resistance.
-
Microneedle Delivery of Risedronate for Osteoporosis
2026-09-27
A 2023 formulation study combined Risedronate Sodium and ursolic acid in nanotransfersomes and incorporated them into a dissolving gelatin microneedle patch. The optimized system showed sustained in vitro release and substantial ex vivo skin permeation, supporting further evaluation of transdermal delivery—not yet demonstrating clinical or in vivo osteoporosis efficacy.
-
Camptothecin Workflows for DNA Damage Research
2026-09-26
Use Camptothecin to connect topoisomerase I inhibition with DNA-damage signaling, cell fate, and autophagy in cancer models. This practical guide pairs a dose-bracketing workflow with clear limits on what a recent yeast adaptation study can—and cannot—tell you about mammalian-cell experiments.